Literature DB >> 1973734

Potential antipsychotic agents. 7. Synthesis and antidopaminergic properties of the atypical highly potent (S)-5-bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide and related compounds. A comparative study.

T Högberg1, T de Paulis, L Johansson, Y Kumar, H Hall, S O Ogren.   

Abstract

(S)-5-Bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide (6) and some related compounds, i.e. the R isomer 7, the 3-hydroxy analogue 8, the desbromo derivative 9, the monomethoxy compound 10, and the 2,4-dimethoxy analogue 11, have been synthesized from the corresponding benzoic acids. The benzamides, lacking o-hydroxy groups, were evaluated for their affinity for the [3H]spiperone binding site and for their inhibition of apomorphine-induced behavioral responses in relation to the effect of the corresponding salicylamides. Besides the 2-hydroxy-3-methoxybenzamide 12 and the related 1,4-benzodioxane (13) and 2,3-dihydrobenzofuran (14), carboxamides were investigated in order to evaluate the stereoelectronic requirements on the 2-methoxy group for the receptor interaction. The study supports the view that the o-methoxy group may adopt coplanar, as well as perpendicular orientations, and maintain the intramolecular hydrogen bonding required in the bioactive conformation. The benzamide 6 was found to be equipotent with the analogous highly active salicylamide 3 (FLB 463) both in vitro and in vivo. In addition, 6 displayed a preferential inhibition of the hyperactivity component of the behavioral syndrome, which is regarded to indicate a low tendency to induce extrapyramidal side effects in man at antipsychotically effective doses. The benzamide class of compounds (6-10) were found to be somewhat more sensitive to the structural modifications than the salicylamide class, i.e. the o-hydroxy-substituted benzamides (2-5). The potent and selective benzamide 6 (FLB 457) is highly suitable for investigations of dopamine D-2 mediated responses and, in radiolabeled form, for receptor binding studies in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1973734     DOI: 10.1021/jm00170a040

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  A novel synthesis of bromobenzenes using molecular bromine.

Authors:  Hamdi Ozkan; Ali Dişli; Yilmaz Yildirir; Lemi Türker
Journal:  Molecules       Date:  2007-11-12       Impact factor: 4.411

2.  NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D2 receptors.

Authors:  H Hall; T Högberg; C Halldin; C Köhler; P Ström; S B Ross; S A Larsson; L Farde
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  [11C]cyclopropyl-FLB 457: a PET radioligand for low densities of dopamine D2 receptors.

Authors:  Anu J Airaksinen; Sangram Nag; Sjoerd J Finnema; Jogeshwar Mukherjee; Sankha Chattopadhyay; Balázs Gulyás; Lars Farde; Christer Halldin
Journal:  Bioorg Med Chem       Date:  2008-05-20       Impact factor: 3.641

4.  Discovery and structure-activity relationship of novel 2,3-dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly(ADP-ribose)polymerase-1 inhibitors.

Authors:  Maulik R Patel; Aaditya Bhatt; Jamin D Steffen; Adel Chergui; Junko Murai; Yves Pommier; John M Pascal; Louis D Trombetta; Frank R Fronczek; Tanaji T Talele
Journal:  J Med Chem       Date:  2014-06-25       Impact factor: 7.446

5.  All-Atom Molecular Dynamics Investigations on the Interactions between D2 Subunit Dopamine Receptors and Three 11C-Labeled Radiopharmaceutical Ligands.

Authors:  Sanda Nastasia Moldovean; Diana-Gabriela Timaru; Vasile Chiş
Journal:  Int J Mol Sci       Date:  2022-02-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.